An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI)

Background Guidelines recommendations regarding anticoagulant therapy after percutaneous coronary intervention (PCI) among patients with atrial fibrillation (AF) rely on retrospective, nonrandomized observational data. Currently, patients are treated with triple-therapy (dual antiplatelet therapy [D...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The American heart journal 2015-04, Vol.169 (4), p.472-478.e5
Hauptverfasser:	Gibson, C. Michael, MS, MD, Mehran, Roxana, MD, Bode, Christoph, MD, Halperin, Johnathan, MD, Verheugt, Freek, MD, Wildgoose, Peter, PhD, van Eickels, Martin, MD, Lip, Gregory Y.H., MD, Cohen, Marc, MD, Husted, Steen, MD, Peterson, Eric, MD, Fox, Keith, MD
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Aged Anticoagulants Atrial Fibrillation - complications Atrial Fibrillation - drug therapy Cardiac arrhythmia Cardiovascular Coronary Angiography Dose-Response Relationship, Drug Drug therapy Drug Therapy, Combination Electrocardiography Factor Xa Inhibitors - administration & dosage Female Follow-Up Studies Heart attacks Humans Male Middle Aged Morpholines - administration & dosage Myocardial Ischemia - complications Myocardial Ischemia - diagnosis Myocardial Ischemia - therapy Percutaneous Coronary Intervention Platelet Aggregation Inhibitors - administration & dosage Retrospective Studies Rivaroxaban Stroke Thiophenes - administration & dosage Ticlopidine - administration & dosage Ticlopidine - analogs & derivatives Treatment Outcome Vitamin K - antagonists & inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!